WATCH: Sarepta presents webinar about new natural history study for individuals living with LGMD2A/R1

Sarepta Therapeutics recently joined C3 to present a community webinar titled “Journey Update for the LGMD2A/R1 Calpainopathy Community.”

During the webinar, Sarepta discussed the essential role for natural history studies throughout the drug development process. They then shared the design of the Journey study, including enrollment criteria, assessments, and travel policies for participants who need to travel to a clinical site. The webinar concluded with a live Q&A session with audience members.

Watch the webinar recording here: